With regard to our study, the main difference between the 2016 and 2021 WHO classifications is that IDH-wildtype gliomas were assigned to WHO grades II, III and IV according to the 2016 WHO classification (grade II diffuse astrocytoma, grade III anaplastic astrocytoma, grade IV glioblastoma). This evidence concerns the gene IDH1 and central nervous system cancer.